Lexeo Therapeutics, Inc.
LXEOFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Lexeo Therapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Lexeo Therapeutics, Inc. — 10-K filed Mar 11, 2024
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 4 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 29, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 2026-03-31 | 1,467,350 | $8.42M | SEC filing |
| GSA CAPITAL PARTNERS LLP | 2026-03-31 | 34,269 | Not shown | SEC filing |
| Bare Financial Services, Inc | 2026-03-31 | 80 | $459 | SEC filing |
| GOLDMAN SACHS GROUP INC | 2026-03-31 | 1,949,885 | $11.2M | SEC filing |
| LOS ANGELES CAPITAL MANAGEMENT LLC | 2026-03-31 | 37,071 | $213K | SEC filing |
| Burkehill Global Management, LP | 2026-03-31 | 125,000 | $718K | SEC filing |
| Sterling Capital Management LLC | 2026-03-31 | 2,191 | $12.6K | SEC filing |
| Tower Research Capital LLC (TRC) | 2026-03-31 | 9,485 | $54.4K | SEC filing |
| CAXTON CORP | 2026-03-31 | 13,943 | $80K | SEC filing |
| CITADEL ADVISORS LLC | 2026-03-31 | 3,834,999 | $22M | SEC filing |
| DIMENSIONAL FUND ADVISORS LP | 2026-03-31 | 1,103,584 | $6.33M | SEC filing |
| BARCLAYS PLC | 2026-03-31 | 12,165 | $69.8K | SEC filing |
| Vanguard Personalized Indexing Management, LLC | 2026-03-31 | 17,565 | $101K | SEC filing |
| MILLENNIUM MANAGEMENT LLC | 2026-03-31 | 1,612,780 | $9.26M | SEC filing |
| NISA INVESTMENT ADVISORS, LLC | 2026-03-31 | 4,865 | $27.9K | SEC filing |
| Paradigm Biocapital Advisors LP | 2026-03-31 | 6,184,134 | $35.5M | SEC filing |
| Frazier Life Sciences Management, L.P. | 2026-03-31 | 4,424,725 | $25.4M | SEC filing |
| STATE STREET CORP | 2026-03-31 | 3,568,242 | $20.5M | SEC filing |
| SIMPLEX TRADING, LLC | 2026-03-31 | 1,240 | $7.12K | SEC filing |
| IFP Advisors, Inc | 2026-03-31 | 203 | $1.17K | SEC filing |
- Each value is checked against Lexeo Therapeutics, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: the filed value is about 1,000 times too small for the share count at Lexeo Therapeutics, Inc.'s share price.
120 filers have only one report here.
Independent insiders buying near the same time
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-05-18 | Otero Jose Manuel · Chief Operating Officer | Common Stock | S — Open market or private sale | −1,302 | 5.07 | SEC filing |
| 2026-05-18 | Townsend Richard Nolan · Chief Executive Officer | Common Stock | S — Open market or private sale | −3,342 | 5.06 | SEC filing |
| 2026-04-06 | Townsend Richard Nolan · Chief Executive Officer | Common Stock | S — Open market or private sale | −55,000 | 5.69 | SEC filing |
| 2026-02-18 | Otero Jose Manuel · Chief Operating Officer | Common Stock | S — Open market or private sale | −3,016 | 6.40 | SEC filing |
| 2026-02-18 | Townsend Richard Nolan · Chief Executive Officer | Common Stock | S — Open market or private sale | −10,173 | 6.38 | SEC filing |
| 2025-11-18 | See Tai Sandi · Chief Development Officer | Common Stock | S — Open market or private sale | −386 | 9.27 | SEC filing |
| 2025-11-18 | Adler Eric · Chief Medical Officer | Common Stock | S — Open market or private sale | −615 | 9.27 | SEC filing |
| 2025-11-18 (amended) | Otero Jose Manuel · Chief Operating Officer | Common Stock | S — Open market or private sale | −721 | 9.27 | SEC filing |
Showing 8 of 14 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-25 | CHOLMONDELEY PAULA H · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +35,000 | SEC filing |
| 2026-06-25 | COOPERSTONE BRENDA · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +35,000 | SEC filing |
| 2026-06-25 | Tanguler Tolga · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +35,000 | SEC filing |
| 2026-06-25 | Agger Mette Kirstine · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +35,000 | SEC filing |
| 2026-06-25 | Altschuler Steven · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +35,000 | SEC filing |
| 2026-06-25 | DIAZ REINALDO M · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +35,000 | SEC filing |
| 2026-06-25 | Van Hauwermeiren Timothy · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +35,000 | SEC filing |
| 2026-04-28 | Sepp-Lorenzino Laura · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +50,000 | SEC filing |
Showing 8 of 20 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.